Skip to main content
SpringerLink
Log in

Prise en charge des tumeurs primitives du foie et des voies biliaires

  • Chapter
Thérapeutique du cancer

  • 754 Accesses

Résumé

Les tumeurs primitives du foie représentent un problème majeur de santé publique dans le monde en raison d’une incidence en permanente progression. En effet, elles font partie des dix cancers les plus fréquents dans le monde (en 5e position chez l’homme avec 442 000 nouveaux cas estimés par an et la 8e position chez la femme avec 184 000 cas estimés par an) [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Borie F, Trétarre B, Bouvierc AM et al. (2009) Primitive liver cancers: epidemiology and geographical study in France. Eur J Gastroenterol Hepatol 21: 984–989

    Article  PubMed  Google Scholar 

  2. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48: S20–S37

    Article  PubMed  CAS  Google Scholar 

  3. Regimbeau JM, Colombat M, Mognol P et al. (2004) Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 10: S69–S73

    Article  PubMed  Google Scholar 

  4. Chevret S, Trinchet JC, Mathieu M et al. (1999) A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 31: 133–141

    Article  PubMed  CAS  Google Scholar 

  5. Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417–422

    PubMed  Google Scholar 

  6. Trinchet JC, Cooperative Group Screening for hepatocellular carcinoma in patients with cirrhosis (2007) A multicenter randomized trial comparing two periodicities of ultrasonographic screening, 3 months vs 6 months. J Hepatol 46(Suppl.1): S56

    Article  Google Scholar 

  7. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208–1236

    Article  PubMed  Google Scholar 

  8. Llovet JM, Ricci S, Mazzaferro V et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Eng J Med 359: 378–390

    Article  CAS  Google Scholar 

  9. Hung H (2005) Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Target 5: 131–138

    Article  CAS  Google Scholar 

  10. Mazzaferro V, Regalia E, Doci R et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl J Med 334: 693–699

    Article  PubMed  CAS  Google Scholar 

  11. Bruix J, Hessheimer AJ, Forner A et al. (2006) New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 25: 3848–3856

    Article  PubMed  CAS  Google Scholar 

  12. Cho YK, Kim JK, Kim MY et al. (2009) Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapy. Hepatology 49: 453–459

    Article  PubMed  Google Scholar 

  13. Arii S, Yamaoka Y, Futagawa S et al. (2000) Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nation-wide survey in Japan. Hepatology 32: 1224–1229

    Article  PubMed  CAS  Google Scholar 

  14. Cheng AL, Kang YK, Chen Z et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10: 25–34

    Article  PubMed  CAS  Google Scholar 

  15. Louafi S, Boige V, Ducreux M et al. (2007) Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma: results of a phase II study. Cancer 109: 1384–1390

    Article  PubMed  CAS  Google Scholar 

  16. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429–442

    Article  PubMed  CAS  Google Scholar 

  17. Girard N, Mornex F (2011) Radiothérapie externe des carcinomes hépatocellulaires. Cancer/Radiothérapie, Elsevier/Masson

    Google Scholar 

  18. Heimbach JK, Haddock MG, Alberts SR et al. (2004) Transplantation for hilar cholangiocarcinoma. Liver Transpl 10,Suppl 2: S65–S68

    Article  PubMed  Google Scholar 

  19. Ortner MEJ, Caca K, Berr F et al. (2003) Successful photodynamic therapy for non resectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125: 1355–1363

    Article  PubMed  Google Scholar 

  20. Oberfield RA, Rossi RL (1998) The role of chemotherapy in the treatment of bile duct cancer. World J Surg 12: 105–108

    Article  Google Scholar 

  21. Glimelius B, Hoffman K, Sjoden PO et al. (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593–600

    Article  PubMed  CAS  Google Scholar 

  22. Eckel F, Schmid RL (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96: 896–902

    Article  PubMed  CAS  Google Scholar 

  23. Valle J, Wasan H, Palmer DH et al. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273–1281

    Article  PubMed  CAS  Google Scholar 

  24. Takada T, Amano H, Yasuda H et al. (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? Cancer 95: 1685–1695

    Article  PubMed  Google Scholar 

  25. Philip PA, Mahoney M, Allmer C et al. (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24: 3069–3074

    Article  PubMed  CAS  Google Scholar 

  26. Bengala C, Bertolini F, Malavasi N et al. (2010) Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 102: 68–72

    Article  PubMed  CAS  Google Scholar 

  27. Malka D, Trarbach T, Fartoux L et al. (2009) A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. Proc Am Soc Clin Oncol abstract 4520

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service interhospitalier de cancérologie Bichat-Beaujon, Hôpital Beaujon, 100, boulevard du Général-Leclerc, 92118, Clichy Cedex

    C. Dreyer, M. Bouattour, E. Raymond & S. Faivre

Authors
  1. C. Dreyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Bouattour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Raymond
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Faivre
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France

About this chapter

Cite this chapter

Dreyer, C., Bouattour, M., Raymond, E., Faivre, S. (2011). Prise en charge des tumeurs primitives du foie et des voies biliaires. In: Thérapeutique du cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0021-9_25

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0021-9_25

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0020-2

  • Online ISBN: 978-2-8178-0021-9

Publish with us

Policies and ethics

Search

Navigation